A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)
Latest Information Update: 03 Jun 2024
At a glance
- Drugs Budesonide (Primary)
- Indications IgA nephropathy
- Focus Registrational; Therapeutic Use
- Acronyms NefIgArd
- Sponsors Calliditas Therapeutics
- 30 May 2024 According to a Calliditas Therapeutics media release, a final decision by the European Commission (EC) on granting a marketing authorisation is anticipated in August 2024.
- 28 May 2024 According to a Calliditas Therapeutics media release, additional efficacy analysis of MAIC for NefIgArd and irbesartan for PROTECT were presented at the ERA 2024 virtually and in Stockholm on May 23 - 26, 2024.
- 18 Apr 2024 Results presented in the Calliditas Therapeutics Media Release.